Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Christian Hinrichs
- Target Recruit Count
- 30
- Registration Number
- NCT05483491
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Centre Hospitalier St Anne
- Target Recruit Count
- 45
- Registration Number
- NCT05468073
- Locations
- 🇫🇷
GHU Saint Anne, Paris, France
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 3
- Registration Number
- NCT05296564
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Aulos Bioscience, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT05267626
- Locations
- 🇺🇸
University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
🇺🇸START Midwest, Grand Rapids, Michigan, United States
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Scripps Health, La Jolla, California, United States
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT05155033
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Ciclosporin Followed by Low-dose IL-2 in Patients with Recently Diagnosed Type 1 Diabetes
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 24
- Registration Number
- NCT05153070
- Locations
- 🇫🇷
Lorenzon Roberta, Paris, France
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04536922
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04426669
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT04383067
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.